Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-backed I/O drug
The checkpoint frenzy in the immuno-oncology sphere has largely focused on blocking the ligand-receptor duo of PD-L1 and PD-1, which cancer cells use to shield themselves from the immune system. Dissatisfied by the ability of PD-L1 agents to go after aggressive, metastatic cancers, a group of UCSF researchers are charting a new path: What if the production of checkpoint proteins could be stopped from the outset?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
